India Backs Four AI-Discovered Drug Candidates With ₹86 Crore

India’s Technology Development Board, under the Department of Science and Technology, signed an agreement to support Bengaluru-based Peptris Technologies and its VIGOR program. The government’s Press Information Bureau announced it on October 12. Support totals ₹86 crore out of a ₹172-crore project. One crore equals ten million, so those figures are ₹860 million and ₹1.72 billion.

The three-year program aims to move four AI-discovered molecular candidates through preclinical validation and preparation for possible clinical trials. The government describes the support as optionally convertible debt. The candidate portfolio addresses areas including neuromuscular disorders, oncology, hair loss, neuropathy and Duchenne muscular dystrophy.

Finding a promising molecule is only the first step toward a medicine. Researchers must test its action and safety in the laboratory, develop a viable formulation and then conduct regulated studies involving people. None of the four candidates is described by the government as an approved drug or proven treatment. The news is about financing the difficult transition from a computational lead to a testable medical product, not about a cure already reaching patients.

Source

• Official release